^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lucicebtide (ST101)

    i
    Other names: ST101
    Company:
    Sapience Therap
    Drug class:
    CEBPB antagonist
    Related drugs:
    12ms
    ST101-101: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=125, Active, not recruiting, Sapience Therapeutics | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    HR positive • BRAF mutation
    |
    temozolomide • abiraterone acetate • lucicebtide (ST101)
    over1year
    ST101-101: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=125, Active, not recruiting, Sapience Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    temozolomide • abiraterone acetate • lucicebtide (ST101)
    2years
    ST101-101: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Sapience Therapeutics
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    HR positive • BRAF mutation
    |
    temozolomide • abiraterone acetate • lucicebtide (ST101)
    2years
    Neoadjuvant treatment with ST101, C/EBPβ antagonist, triggers necrosis as a pathological response in newly diagnosed GBM patients. Tissue-based analysis from a surgical window of opportunity trial. (SNO 2023)
    After surgery, patients will continue ST101 QW + standard chemoradiation with temozolomide. ndGBM treated with neoadjuvant ST101 monotherapy shows extensive treatment effects on the tumors that have never been treated with chemoradiation. Stability of enhancing lesions after ST101 monotherapy may not reflect the extent of treatment effect as revealed by treatment-related necrosis in the resected tissue. Analyses of the pharmacodynamics effects of ST101 on GBM cells and tumor microenvironment will be completed and presented.
    Clinical
    |
    temozolomide • lucicebtide (ST101)
    over3years
    ST101-101: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Sapience Therapeutics | Trial primary completion date: Oct 2022 --> Oct 2023
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    HR positive • BRAF mutation
    |
    temozolomide • abiraterone acetate • lucicebtide (ST101)
    4years
    ST101-101: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=162, Recruiting, Sapience Therapeutics | Trial completion date: Jan 2023 --> Jan 2024
    Clinical • Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    HR positive • BRAF mutation
    |
    temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)
    over5years
    Clinical study of ST101 in Patients with Advanced Cancer (clinicaltrialsregister.eu)
    P1/2, N=156, Ongoing, Sapience Therapeutics, Inc.
    Clinical • New P1/2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    lucicebtide (ST101)